<DOC>
	<DOCNO>NCT00110708</DOCNO>
	<brief_summary>The purpose study determine human immunoglobulin give mouth twice day effective treating persistent gastrointestinal ( GI ) problem diarrhea , constipation , abdominal pain , bloating , child autism .</brief_summary>
	<brief_title>Safety Efficacy Study Treatment Intestinal Problems Associated With Autism</brief_title>
	<detailed_description>Autistic GI Dysfunction ( AGID ) term describes constellation GI sign symptom often find child autistic disorder , include abdominal pain , constipation , chronic diarrhea , alternate constipation diarrhea , gaseousness , bloating , reflux . The objective study assess potential efficacy oral immunoglobulin reduce wide range GI symptoms child adolescent diagnose autistic disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Signs Symptoms , Digestive</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Male female 2 year 18 year age ( , inclusive 18th birthday ) Diagnosis autistic disorder corroborate Autism Diagnostic Interview Revised ( ADIR ) assessment perform certified investigator Physician Clinical Global Impression Severity ( Autistic Disorder ) History chronic , persistent gastrointestinal disturbance No elective change medication , diet intervention , behavioral therapy study ( 18 week total ) Evidence gastrointestinal infection GI abnormality A know diagnosis gastrointestinal pathology Antibiotic and/or antifungal ( e.g . nystatin ) medication Chelation therapy Medication affect gastrointestinal transit Planned use prohibit drug agent could affect GI transit Changes diet intervention within 30 day prior screen visit Changes alternative medical therapy dietary supplement within 30 day prior screen visit Adding and/or change behavior modification psychotherapy participation study Adding change psychotropic medication participation study DSMIV diagnosis pervasive developmental disorder autistic disorder Evidence seizure disorder , diagnosis fragile X syndrome , tuberous sclerosis complex , liver disease , pancreatic disease , cystic fibrosis , chronic infection Previous gastrointestinal surgery Pregnancy Participation another investigational study Significant deviation normal laboratory test value baseline IgA deficiency ( serum IgA &lt; 5 mg/dL ) A history severe hypersensitivity human immunoglobulin Treatment human immunoglobulin and/or immunoglobulin product Any concurrent medication would compromise subject 's tolerance drug compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>autism</keyword>
	<keyword>gastrointestinal dysfunction</keyword>
	<keyword>autistic disorder</keyword>
	<keyword>diarrhea</keyword>
	<keyword>constipation</keyword>
	<keyword>abdominal pain</keyword>
	<keyword>gastrointestinal problem associate autism</keyword>
	<keyword>immune globulin</keyword>
	<keyword>immunoglobulin</keyword>
	<keyword>Immunoglobulins , Intravenous</keyword>
	<keyword>Intestinal Mucosa/immunology/pathology</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Autistic Disorder/*drug therapy</keyword>
	<keyword>Child Behavior/*drug effect</keyword>
	<keyword>Constipation/drug therapy</keyword>
	<keyword>Diarrhea/drug therapy</keyword>
	<keyword>Gastrointestinal Agents/*therapeutic use</keyword>
</DOC>